Warning letter
Atrium Inc.: warning letter of Nov 2, 2012
FDA warning letter 292238 · Minneapolis District Office
Key facts
| Reference number | 292238 |
|---|---|
| Company | Atrium Inc. |
| Subject | CGMP/Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements/Adulterated |
| Issue date | Nov 2, 2012 |
| Posted date | Nov 2, 2012 |
| Issuing office | Minneapolis District Office |
| Product type | Food/Cosmetics |
| CFR sections cited | 189.5(c), 189.5(d)(1), 111, 111.70, 111.73, 111.103, 111.205, 111.210, 111.260, 111.553, 111.560, 111.70(b) and 20 more |
| Inspection city | Wautoma |
| Inspection ZIP | 54982 |
| Inspection start date | Jan 10, 2012 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: